Compare TILE & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TILE | NTLA |
|---|---|---|
| Founded | 1973 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.8B |
| IPO Year | 1994 | 2016 |
| Metric | TILE | NTLA |
|---|---|---|
| Price | $37.42 | $12.71 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 23 |
| Target Price | ★ $36.00 | $20.02 |
| AVG Volume (30 Days) | 477.4K | ★ 3.3M |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.29% | N/A |
| EPS Growth | ★ 32.43 | 27.43 |
| EPS | ★ 1.28 | N/A |
| Revenue | ★ $1,386,854,000.00 | $67,671,000.00 |
| Revenue This Year | $6.72 | N/A |
| Revenue Next Year | $5.61 | $62.75 |
| P/E Ratio | $28.91 | ★ N/A |
| Revenue Growth | 5.41 | ★ 16.92 |
| 52 Week Low | $24.40 | $7.95 |
| 52 Week High | $40.50 | $28.24 |
| Indicator | TILE | NTLA |
|---|---|---|
| Relative Strength Index (RSI) | 49.56 | 55.01 |
| Support Level | $27.29 | $11.55 |
| Resistance Level | $40.07 | $13.88 |
| Average True Range (ATR) | 1.08 | 0.63 |
| MACD | -0.36 | 0.10 |
| Stochastic Oscillator | 11.91 | 69.18 |
Interface Inc is engaged in the design, production, and sale of carpet tiles. It also provides Luxury Vinyl tiles and rubber flooring. The company mainly targets corporate and noncorporate office markets, including government, education, healthcare, hospitality, and retailers. Its geographical segments include the Americas, Europe, and Asia-Pacific. It has two operating and reportable segments- namely Americas (AMS) and Europe, Africa, Asia and Australia (collectively EAAA). Key revenue is generated from AMS segment. Its products include: ESD, Acoustic, Extreme Wear, and Quick Installation System (nTx).
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.